Health insurance company Clover Health (NASDAQ: CLOV) will be announcing earnings results this Tuesday afternoon. Here’s what you need to know.
Clover Health beat analysts’ revenue expectations by 1.7% last quarter, reporting revenues of $477.6 million, up 34.1% year on year. It was a satisfactory quarter for the company, with full-year EBITDA guidance beating analysts’ expectations but a significant miss of analysts’ EPS estimates. It added 2,905 customers to reach a total of 106,323.
Is Clover Health a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, analysts are expecting Clover Health’s revenue to grow 42.3% year on year to $471.1 million, improving from the 8.2% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.02 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Clover Health has missed Wall Street’s revenue estimates five times over the last two years.
Looking at Clover Health’s peers in the health insurance providers segment, some have already reported their Q3 results, giving us a hint as to what we can expect. CVS Health delivered year-on-year revenue growth of 7.8%, beating analysts’ expectations by 4.1%, and Centene reported revenues up 18.2%, topping estimates by 3.7%. CVS Health traded down 6.7% following the results while Centene was up 5.5%.
Read our full analysis of CVS Health’s results here and Centene’s results here.
Investors in the health insurance providers segment have had steady hands going into earnings, with share prices flat over the last month. Clover Health is up 36.2% during the same time and is heading into earnings with an average analyst price target of $3.37 (compared to the current share price of $3.57).
When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
